App-Quantinova.ai

DURABILITY OF CERTOLIZUMAB PEGOL IN PATIENTS WITH RHEUMATOID ARTHRITIS OR PSORIASIS OVER THREE YEARS: AN ANALYSIS OF POOLED CLINICAL TRIAL DATA

V. Bykerk - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Rheumatoid arthritis

Certolizumab pegol

EARLY AND SUSTAINED RESPONSES WITH ANIFROLUMAB TREATMENT IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IN 2 PHASE 3 TRIALS

E. F. Morand - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

MDX1333

DRUG-RELATED PANCYTOPENIA AND LEUKOPENIA IN RHEUMATOID ARTHRITIS: ARE ALL CSDMARDS EQUAL?

L. Carmona - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

N/A

EFFECT OF NINTEDANIB ON PROGRESSION OF INTERSTITIAL LUNG DISEASE (ILD) IN PATIENTS WITH AUTOIMMUNE DISEASE-RELATED ILDS: FURTHER DATA FROM THE INBUILD TRIAL

E. Matteson - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Nintedanib

EFFECT OF RITUXIMAB ON IMMUNOGLOBULIN LEVELS AND RISK OF ASSOCIATED INFECTION

S. Khalid - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Rituximab

EFFECT OF RITUXIMAB OR TUMOUR NECROSIS FACTOR INHIBITORS ON LUNG INFECTION AND 5-YEAR SURVIVAL IN RHEUMATOID ARTHRITIS-ASSOCIATED BRONCHIECTASIS

M. Y. MD Yusof - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Rituximab

EFFECT OF SEX ON DISEASE CHARACTERISTICS AND DISEASE IMPACT IN PATIENTS WITH PSORIATIC ARTHRITIS (PsA): INSIGHTS FROM THE REAL-WORLD, OBSERVATIONAL MULTINATIONAL PsABio COHORT

M. T. Nurmohamed - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

N/A

EFFECTS OF NINTEDANIB IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED ILD (SSC-ILD) AND DIFFERING EXTENTS OF SKIN FIBROSIS: FURTHER ANALYSES OF THE SENSCIS TRIAL

Y. Allanore - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Scleroderma

Nintedanib

EFFECTS OF GUSELKUMAB, A MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THE P19-SUBUNIT OF INTERLEUKIN-23, ON DACTYLITIS AND ENTHESITIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: POOLED RESULTS THROUGH WEEK 24 FROM TWO PHASE 3 STUDIES

D. Mcgonagle - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

Interleukin

EFFICACY AND SAFETY OF 108 WEEKS’ BIMEKIZUMAB TREATMENT IN PATIENTS WITH PSORIATIC ARTHRITIS: INTERIM RESULTS FROM A PHASE 2 OPEN-LABEL EXTENSION STUDY

I. Mcinnes - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

bimekizumab

EFFICACY AND SAFETY OF BIMEKIZUMAB IN ANKYLOSING SPONDYLITIS: 48-WEEK PATIENT-REPORTED OUTCOMES FROM A PHASE 2B, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY

D. Van der Heijde - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Ankylosing spondylitis

bimekizumab

EFFICACY AND SAFETY OF GUSELKUMAB, A MONOCLONAL ANTIBODY SPECIFIC TO THE P19-SUBUNIT OF INTERLEUKIN-23, THROUGH WEEK 52 OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY CONDUCTED IN BIOLOGIC-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS

I. Mcinnes - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

Interleukin

EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS BASED ON CONCOMITANT CONVENTIONAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (CDMARD) USE: RESULTS FROM SPIRIT-P1 AND SPIRIT-P2

L. C. Coates - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

Hydroxychloroquine

EFFICACY AND SAFETY OF FILGOTINIB, A SELECTIVE JANUS KINASE 1 INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: SUBGROUP ANALYSES FROM A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL (EQUATOR)

P. Helliwell - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

Filgotinib

EFFICACY AND SAFETY OF NINTEDANIB IN PATIENTS WITH AUTOIMMUNE DISEASE-RELATED INTERSTITIAL LUNG DISEASE TREATED WITH DMARDS AND/OR GLUCOCORTICOIDS AT BASELINE

M. Aringer - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Interstitial lung disease

Glucocorticoid

EFFICACY AND SAFETY OF THE COMBINATION OF APOCYNIN AND PAEONOL (APPA) IN PATIENTS WITH OSTEOARTHRITIS: AN UNCONTROLLED PATIENT CASE SERIES

N. Larkins - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

Apocynin

EFFICACY AND SAFETY OF ROMILKIMAB IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC): RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 24-WEEK, PROOF OF CONCEPT STUDY

Y. Allanore - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Scleroderma

N/A

EFFICACY AND SAFETY OF THE PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST CR6086 ADDED TO METHOTREXATE IN DMARD-NAÏVE EARLY RA PATIENTS: A PHASE 2 RANDOMIZED CONTROLLED TRIAL

K. Pavelka - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Prostaglandin

EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-PSA-2): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL

M. C. Genovese - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

ABT-494

EFFICACY AND SAFETY OF UPADACITINIB MONOTHERAPY IN MTX-NAÏVE PATIENTS WITH EARLY ACTIVE RA RECEIVING TREATMENT WITHIN 3 MONTHS OF DIAGNOSIS: A POST-HOC ANALYSIS OF THE SELECT-EARLY

M. C. Kapetanovic - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

ABT-494

Filters

45280 Abstracts